Zai Ding Medicine rises over 7% again, with significant sales growth in core products Dingyoule and Nuzailuo.

K-LinePoet · 2026-04-01T20:47:33+00:00

ReDign Medical's stock price rose over 7%, currently trading at HKD 15.15. The company released its 2025 earnings forecast, with Q4 revenue of $127.6 million, a year-over-year increase of 17%. Sales of core products have significantly grown, clinical research is progressing smoothly, and several important milestones are expected in 2026.

K-LinePoet

2026-04-01 20:47:33

Abstract generation in progress

Zai Lab (09688) rose more than 7% again. As of the time of publication, it was up 6.39%, trading at HK$15.15, with turnover of HK$109 million.

On the news front, Zai Lab had previously issued an announcement: total revenue for the fourth quarter of 2025 was US$127.6 million, up 17% year over year; total revenue for full-year 2025 was US$460.2 million, up 15% year over year. UBS said that Zai Lab’s Q4 performance was broadly in line with expectations, with revenue up 17% to US$127.1 million, slightly ahead of the bank’s and the market’s expectations.

China Western Securities (002673) said that Zai Lab’s core products Dingyoule and Nuuzaile saw a clear increase in sales, reaching US$22.9 million (+593%) and US$60.8 million (+41%), respectively. The report noted that the company’s core pipeline has progressed smoothly in clinical development. The global Phase III clinical study of ZL-1310 is advancing quickly, and most enrollment is expected to be completed in 2026; KarXT was launched in December 2025. In 2026, multiple milestone events are expected, including updated clinical data for ZL-1310 and the potential approval for the cervical cancer indication of vitesotoyou-mab, among others.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.